Financials
Financial year 2025
EORTC Cancer Research Fund from Sint-Lambrechts-Woluwe, company number BE0416340628, closed financial year 2025 with a result of € -3,188 after tax. For that financial year EORTC Cancer Research Fund recorded a gross margin of € -8,472 and equity of € 308,824. Compared with financial year 2024, the result moved from € 44,344 to € -3,188. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on April 8, 2026.
€ 308,824
▼ 1% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -3,188
▼ still € 44,344 profit in 2024
Profit after tax over the fiscal year.
€ 335,486
▲ 3% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 108,824.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 1,669,086 | € 817 | € 97,906 | € -8,472 | ▼ € 106,378 |
| Profit after taxes | € -22,391 | € -54,546 | € 44,344 | € -3,188 | ▼ € 47,532 |
| Equity | € 322,215 | € 267,669 | € 312,013 | € 308,824 | ▼ 1% |
| Total debts | € 1,762,107 | € 1,502,651 | € 118,430 | € 166,457 | ▲ 41% |
| Cash | € 1,801,971 | € 1,540,840 | € 325,504 | € 335,486 | ▲ 3% |
| Retained profit | € 122,215 | € 67,669 | € 112,013 | € 108,824 | ▼ 3% |
| Balance sheet total | € 2,084,321 | € 1,770,320 | € 430,442 | € 475,281 | ▲ 10% |
Key figures of EORTC Cancer Research Fund, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to EORTC Cancer Research Fund?
What happened at EORTC Cancer Research Fund in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 3,188 (▼ € 47,532 vs 2024). Source: NBB ↗
- Denis Albert Lacombe stepped down as director. NBB
- Guy Beniada stepped down as director. NBB
- Diego Comte du Monceau de Bergendal stepped down as director. NBB
- Denis Albert Lacombe became a director. NBB
- Guy Beniada became a director. NBB
- Diego Comte du Monceau de Bergendal became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 22,391 loss in 2022 to € 3,188 loss in 2025.
Paid € 1,848 in corporate taxes since 2022.
Best year ever: 2024, with € 44,344 profit.
Management
Directors
According to the 2025 annual accounts
Denis Albert Lacombe
Director
since 2022 · until 2026
Guy Beniada
Director
since 2022 · until 2026
Diego Comte du Monceau de Bergendal
Chairman of the board
since 2022 · until 2026
Establishments
Establishment units
Physical locations of this company
Emmanuel Mounierlaan 83
1200 Sint-Lambrechts-Woluwe
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.
All companies at this address →EUROPESE ORGANISATIE VOOR ONDERZOEK EN BEHANDELING VAN KANKER - ORGANISATION EUROPEENNE POUR LA RECHERCHE ET LE TRAITEMENT DU CANCER - EUROPEAN ORGANI
€ 52.3 million revenue · 2025
ILSI Europe
€ 1.2 million gross margin · 2025
EBC Council
€ -25,566 gross margin · 2025
EUROPEAN SOCIETY OF SURGICAL ONCOLOGY - SOCIETE EUROPEENNE D'ONCOLOGIE CHIRURGICALE - EUROPESE GEMEENSCHAP VOOR CHIRURGISCHE ONCOLOGIE
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0416.340.628
- VAT number
- BE 0416.340.628
- Registered office
- Emmanuel Mounierlaan 83, 1200 Sint-Lambrechts-Woluwe
- Names & denominations
- EORTC Cancer Research Fund
- Enterprise type
- Rechtspersoon
- Legal form
- International scientific organisation under Belgian law
- Legal situation
- Normale toestand
- Start date
- 13 September 1976
- Peppol
- Active · Active since 22 Aug 2025